New York-based Terran Biosciences inked a deal with Paris-based Sanofi for two late-stage central nervous system (CNS) assets. Details are sparse, but the company plans to advance them for neurological and psychiatric indications, which were not specified.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,